Daiichi Sankyo Vaccine Development Start clinical trials around March next year New Corona June 12 19:10
Pharmaceutical giant Daiichi Sankyo has decided to embark on the development of a new coronavirus vaccine. We will start clinical trials around March next year, and we will work to supply them as soon as possible.
In April, Daiichi Sankyo launched a cross-company task force aimed at research and development of new coronavirus vaccines and therapeutic agents, and will proceed with research utilizing its own patents and technologies. It was
As a result, when a prototype vaccine based on gene therapy technology was used in animal experiments, it was confirmed that antibodies could be produced against the new coronavirus, so the company decided to embark on full-scale vaccine development. I decided.
In the future, we will start clinical trials around March next year and work on improving the supply system.
Daiichi Sankyo says, "We would like to work as a domestic pharmaceutical company to provide vaccines as soon as possible."
Regarding the new coronavirus vaccine in Japan, major pharmaceutical company "Shionogi Pharmaceutical" and bio-venture "Anges" have started development together with research institutions and universities, and the movement toward early supply is accelerating. I will.